Edition:
United Kingdom

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

2.58USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$2.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,460
52-wk High
$6.64
52-wk Low
$2.27

Latest Key Developments (Source: Significant Developments)

Novan Expands Nitric Oxide Dermatology Partnership With Sato In Japan
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Novan Inc ::NOVAN EXPANDS NITRIC OXIDE DERMATOLOGY BUSINESS PARTNERSHIP WITH SATO IN JAPAN.NOVAN - TO RECEIVE UPFRONT CASH CONSIDERATION OF ABOUT 1.25 BILLION JPY, PAYABLE OVER NEXT 12 MONTHS.NOVAN INC - EXPANDED LICENSE AGREEMENT ADDS SB206 FOR TREATMENT OF VIRAL SKIN INFECTIONS.  Full Article

Novan's Phase 2 Molluscum Contagiosum Trial Fully Enrolled Top Line Results Targeted In November
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Novan Inc ::NOVAN’S PHASE 2 MOLLUSCUM CONTAGIOSUM TRIAL FULLY ENROLLED: TOP LINE RESULTS TARGETED IN NOVEMBER.NOVAN’S PHASE 2 MOLLUSCUM CONTAGIOSUM TRIAL FULLY ENROLLED: TOP LINE RESULTS TARGETED IN NOVEMBER.NOVAN INC - PENDING RESULTS OF PHASE 2 TRIAL, WILL REQUEST AN END-OF-PHASE 2 MEETING WITH FDA AS EARLY AS POSSIBLE DURING Q1 OF 2019.NOVAN INC - MEETING WITH FDA WOULD ENABLE CO TO DISCUSS AND AGREE ON A PHASE 3 DEVELOPMENT PLAN FOR MOLLUSCUM.  Full Article

Novan Receives FDA Guidance For SB204 And Acne Indication
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Novan Inc ::NOVAN RECEIVES FDA GUIDANCE FOR SB204 AND ACNE INDICATION.NOVAN INC - WRITTEN MINUTES RECEIVED FROM TYPE C MEETING WITH FDA.NOVAN - FDA NOTED THERE WERE NO ADDITIONAL SAFETY REQUIREMENTS, THAT ONE ADDITIONAL PIVOTAL TRIAL - IN MODERATE-TO-SEVERE ACNE- WOULD BE REQUIRED.NOVAN INC - FINALIZING CLINICAL DEVELOPMENT PLANS FOR SB204 AND ACNE INDICATION FOR U.S. MARKET.NOVAN - FDA CONFIRMRF NEED FOR 1 ADDITIONAL PIVOTAL TRIAL FOR MODERATE-TO-SEVERE ACNE OR, ADDITIONAL PRELIMINARY TRIALS FOR SEVERE-ONLY PATIENTS.  Full Article

Novan Inc Qtrly Loss Per Share $0.29
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Novan Inc ::NOVAN INC QTRLY LOSS PER SHARE $0.29.  Full Article

Reedy Creek Investments Reports 26.4 Percent Stake In Novan Inc
Monday, 22 Jan 2018 

Jan 22 (Reuters) - REEDY CREEK INVESTMENTS ::REEDY CREEK INVESTMENTS LLC REPORTS 26.4 PERCENT STAKE IN NOVAN INC AS OF JANUARY 9 - SEC FILING.  Full Article

Novan Says Interim CFO William Hodges To Step Down
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Novan Inc ::NOVAN INC - WILLIAM L. HODGES, INTERIM CHIEF FINANCIAL OFFICER NOTIFIED THE CO OF HIS DECISION TO STEP DOWN EFFECTIVE JANUARY 19, 2018.NOVAN SAYS ‍EXPECTS TO HIRE A PERMANENT CHIEF FINANCIAL OFFICER IN FIRST HALF OF 2018 - SEC FILING​.  Full Article

Novan Announces Pricing Of $38.0 Mln Offering Of Common Stock And Warrants
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES PRICING OF $38.0 MILLION OFFERING OF COMMON STOCK AND WARRANTS.NOVAN- PRICING OF OFFERING OF 10 MILLION SHARES OF COMMON STOCK, WARRANTS TO BUY UP TO 10 MILLION SHARES OF COMMON STOCK WITH AN EXERCISE PRICE OF $4.66.NOVAN INC - SHARES AND WARRANTS ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $3.80 PER SHARE AND ACCOMPANYING WARRANT.  Full Article

Novan Announces Proposed Public Offering Of Common Stock And Warrants
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Novan Inc ::NOVAN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.  Full Article

Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414.NOVAN INC - ‍ TOP LINE RESULTS FROM PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414​ ARE TARGETED FOR Q3 OF 2018.NOVAN INC - ‍TOP LINE RESULTS ARE TARGETED FOR Q2 OF 2018 FROM PREVIOUSLY ANNOUNCED PHASE 1B CLINICAL TRIAL WITH SB414 FOR TREATMENT OF PSORIASIS​.  Full Article

Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Novan Inc ::Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​.Novan Inc - ‍proposed Phase 3 trial would be executed by third party's dermatology drug development team​.Novan Inc - a ‍new entity established by third party to provide capital to fund, expertise to execute additional Phase 3 pivotal trial for sb204​.  Full Article

Photo

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 (362,663 pounds) gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.